Patent classifications
C07C47/277
MAGNETIC FERROCENYL-FUNCTIONALIZED NANOPARTICLE
A functionalized magnetic nanoparticle including an organometallic sandwich compound and a magnetic metal oxide. The functionalized magnetic nanoparticle may be reacted with a metal precursor to form in a catalyst for various CC bond forming reactions. The catalyst may be recovered with ease by attracting the catalyst with a magnet.
PHOSPHINE SUBSTITUTED FERROCENYL COMPLEX
A functionalized magnetic nanoparticle including an organometallic sandwich compound and a magnetic metal oxide. The functionalized magnetic nanoparticle may be reacted with a metal precursor to fol in a catalyst for various CC bond forming reactions. The catalyst may be recovered with ease by attracting the catalyst with a magnet.
PHOSPHINE SUBSTITUTED FERROCENYL COMPLEX
A functionalized magnetic nanoparticle including an organometallic sandwich compound and a magnetic metal oxide. The functionalized magnetic nanoparticle may be reacted with a metal precursor to fol in a catalyst for various CC bond forming reactions. The catalyst may be recovered with ease by attracting the catalyst with a magnet.
PHOSPHINE SUBSTITUTED FERROCENYL COMPLEX
A functionalized magnetic nanoparticle including an organometallic sandwich compound and a magnetic metal oxide. The functionalized magnetic nanoparticle may be reacted with a metal precursor to fol in a catalyst for various CC bond forming reactions. The catalyst may be recovered with ease by attracting the catalyst with a magnet.
ORGANIC COMPOUND, THREE-DIMENSIONAL ORGANIC FRAMEWORK FORMED BY USING ORGANIC COMPOUND, SEPARATION SIEVE AND OPTICAL LAYER, WHICH COMPRISE ORGANIC FRAMEWORK, AND OPTICAL DEVICE COMPRISING OPTICAL LAYER AS OPTICAL AMPLIFICATION LAYER
An organic compound, a three-dimensional organic structure formed by using the organic compound, a separation sieve and an optical layer having the organic structure, and an optical device having the optical layer as an optical amplification layer are provided. The organic structure includes a plurality of organic molecules self-assembled by non-covalent bonding. Each of the unit organic molecules has an aromatic ring, a first pair of substituents being connected to immediately adjacent positions of substitutable positions of the aromatic ring, and a second pair of substituents being connected to immediately adjacent positions of remaining substitutable positions of the aromatic ring. The unit organic molecules are self-assembled by van der Waals interaction, London dispersion interaction or hydrogen bonding between the first and the second pairs of the substituents and by pi-pi interactions between the aromatic rings.
Carbidopa and L-dopa prodrugs and methods of use
- Benoit Cardinal-David ,
- Vincent S. Chan ,
- Brian P. Enright ,
- Ye Huang ,
- Alexander D. Huters ,
- Russell C. Klix ,
- Scott W. Krabbe ,
- Philip R. Kym ,
- Yanbin Lao ,
- Xiaochun Lou ,
- Sean E. Mackey ,
- Mark A. Matulenko ,
- Peter T. Mayer ,
- Christopher P. Miller ,
- James Stambuli ,
- Eric A. Voight ,
- Zhi Wang ,
- Geoff G. Zhang ,
- Valentino J. Stella
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
Carbidopa and L-dopa prodrugs and methods of use
- Benoit Cardinal-David ,
- Vincent S. Chan ,
- Brian P. Enright ,
- Ye Huang ,
- Alexander D. Huters ,
- Russell C. Klix ,
- Scott W. Krabbe ,
- Philip R. Kym ,
- Yanbin Lao ,
- Xiaochun Lou ,
- Sean E. Mackey ,
- Mark A. Matulenko ,
- Peter T. Mayer ,
- Christopher P. Miller ,
- James Stambuli ,
- Eric A. Voight ,
- Zhi Wang ,
- Geoff G. Zhang ,
- Valentino J. Stella
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-?-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHOD FOR PRODUCING THE SAME
A compound represented by a formula [1D] as shown below (wherein R.sup.1A, R.sup.1B, R.sup.2A, R.sup.2B, R.sup.3A and R.sup.3B represent a hydrogen atom, an optionally substituted C.sub.1-6 alkyl group, and the like) is useful as an intermediate for producing a thionucleoside, and the production method of the present invention is useful as a method for producing a thionucleoside.
##STR00001##
SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-?-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHOD FOR PRODUCING THE SAME
A compound represented by a formula [1D] as shown below (wherein R.sup.1A, R.sup.1B, R.sup.2A, R.sup.2B, R.sup.3A and R.sup.3B represent a hydrogen atom, an optionally substituted C.sub.1-6 alkyl group, and the like) is useful as an intermediate for producing a thionucleoside, and the production method of the present invention is useful as a method for producing a thionucleoside.
##STR00001##
Functionalized magnetic nanoparticle, a catalyst, a method for forming C—C bonds
A functionalized magnetic nanoparticle including an organometallic sandwich compound and a magnetic metal oxide. The functionalized magnetic nanoparticle may be reacted with a metal precursor to form a catalyst for various CC bond forming reactions. The catalyst may be recovered with ease by attracting the catalyst with a magnet.